Microfluidic Development of Targeted Therapy-Loaded Biomimetic Nanoparticles

Microfluidic Development of Nanoparticles for Melanoma Treatment

Introduction to the Study

  • Objective: The study aims to improve the treatment of metastatic melanoma (MM) using targeted therapy-loaded biomimetic nanoparticles (NPs).
  • Techniques: Utilizes microfluidics for the production of cell membrane-modified NPs that enhance targeting efficacy and minimize immune clearance.

Key Terminology

  • Microfluidics: A technology dealing with the precise control and manipulation of fluids at the microscale.
  • Biomimetic: Refers to materials or systems that imitate natural biological structures and functions.
  • Hybrid Liposomes: Liposomes that are modified with cell membranes to enhance targeting capabilities.
  • Lenvatinib (Lenva) & Cobimetinib (Cob): Anti-melanoma drugs employed in the study.

The Need for Enhanced Therapies

  • Current therapies for metastatic melanoma need optimization due to their limitations in targeting and efficacy.
  • Traditional NPs often suffer from rapid clearance by the immune system, requiring new strategies for effective drug delivery.

Methodology

1. Production of Hybrid Liposomes

  • Cell Membrane (CM) Sourcing: CMs are extracted from a BRAF wild-type metastatic melanoma cell line using a freeze-thaw and sonication protocol.
  • Microfluidic Technique: Employs gentle sonication and precise flow control to fuse CMs with synthetic liposomes, creating hybrid liposomes.
  • Characterization of Hybrid Liposomes: Evaluation of size, surface charge (ζ-potential), and drug encapsulation efficiency.

2. Characterization Studies

  • Hybrid liposomes exhibited significant increases in cellular uptake compared to conventional liposomes, showing enhanced homotypic targeting.
  • Particle Size Distribution: Monitored to ensure uniformity and reproducibility in hybrid liposome production, achieving high encapsulation efficiencies for both Cob and Lenva (>70%).

Key Findings

Efficacy of Hybrid Liposomes

  • Cellular Uptake: Hybrid liposomes showed an 8-fold increased uptake in cells from which CMs were sourced, indicating effective targeting.
  • In vitro Viability Tests: Hybrid formulations reduced cell viability more significantly than free drugs or conventional liposome formulations, demonstrating superior anti-tumor activity.

Mechanistic Insights

  • Endocytosis Pathways: Evaluated using various inhibitors to guide understanding of NPs uptake mechanisms, confirming energy-dependent endocytosis.
  • Haemolysis Tests: Assessed the safety profile, revealing negligible toxicity associated with hybrid liposome formulations, critical for in vivo applications.

Conclusions

  • Promising Therapeutic Tool: The study highlights the potential of CM-modified hybrid liposomes for enhanced therapeutic delivery in melanoma treatment, paving the way for personalized medicine.
  • Scalability and Consistency: Microfluidics offers a robust method for producing standardized NPs, making large-scale production feasible and adaptable for clinical applications.